Blog
RSS FeedPosted by Michael Wonder on 05 Aug 2015
PTAC recommended the listing of Perjeta (pertuzumab) for patients with metastatic breast cancer
At its meeting on 13-14 February 2014, the Committee reviewed an application from Roche for the funding of pertuzumab (Perjeta) ...